Andrew Kuykendall, a doctor from Moffitt Cancer Center, and Lucia Masarova, affiliated with MD Anderson Cancer Center, dive into the complexities of polycythemia vera (PV) and essential thrombocythemia (ET). They discuss unique challenges in treating adolescent and young adult patients, emphasizing personalized treatment strategies. The duo critiques current clinical trials and advocates for collaborative research to improve outcomes. They also explore the feasibility of early interventions and the importance of defining clear treatment goals.

Experts discuss the mutational landscape and challenges of treating accelerated-phase myeloproliferative neoplasms (MPNs). They highlight the need for novel treatment strategies, including targeted and combination therapies, to improve outcomes.